乳腺癌肝转移治疗策略的研究进展：一项综述
Research advances in treatment strategies for breast cancer liver metastases: A comprehensive review.
作者信息
Yan Liping, Tao Peng
机构信息
Department of Breast Surgery, Jiangxi Maternal and Child Health Hospital, Nanchang 330006, Jiangxi, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China, Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education/Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Nanning 530021, Guangxi, China.
出版信息
ILIVER. 2025 Aug 13;4(3):100186. doi: 10.1016/j.iliver.2025.100186. eCollection 2025 Sep.
Breast cancer is the most prevalent malignancy in women globally, with metastatic disease accounting for approximately 90 % of breast cancer-related deaths. The development of breast cancer liver metastases in patients not only significantly reduces survival rates but also severely impairs quality of life. This review systematically examines therapeutic advances in the treatment of breast cancer liver metastases from 2010 to 2023, focusing on novel targeted agents (CDK4/6 inhibitors, PI3K/mTOR pathway inhibitors), immune checkpoint inhibitors, and local interventions. We provide evidence-based recommendations to optimize personalized treatment strategies and improve clinical outcomes for patients with breast cancer liver metastases.
乳腺癌是全球女性中最常见的恶性肿瘤，转移性疾病约占乳腺癌相关死亡人数的90%。乳腺癌肝转移患者的出现不仅显著降低了生存率，还严重损害了生活质量。本综述系统地研究了2010年至2023年乳腺癌肝转移治疗的进展，重点关注新型靶向药物（CDK4/6抑制剂、PI3K/mTOR通路抑制剂）、免疫检查点抑制剂和局部干预措施。我们提供基于证据的建议，以优化个性化治疗策略，改善乳腺癌肝转移患者的临床结局。
Zotero 插件